RETINOSTAT

Owners

Goods & Services

Gene therapy and prophylaxis products, namely, gene delivery, gene transfer, gene regulation and gene modulation for the treatment of [ blood disorders, cancers, diseases of the nervous system, ] macular degeneration, diabetic retinopathy, [ diabetes, inflammatory and auto-immune diseases, vascular disorders, ] disorders arising from improper vascularisation and single gene disorders; pharmaceutical substances and preparations for use in the medical industry, namely, vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic/angiogenic molecules, retroviral vector and retroviral vector manufacturing preparations, all for use in gene delivery technologies, vector production technologies and neurogenomics products; chemical products for use in medical science, particularly for treatment of disease of the eye, vascular and neovascularisation disorders and retinopathy; pharmaceutical and biochemical preparations for the treatment of macular degeneration and retinopathy [ and angiogenesis; ] instruments and apparatus for the administration of gene and [ antibody-based ] therapy and prophylaxis preparations and substances, namely, pre-filled vials, syringes and injectors for medical purposes

Scientific and medical research and development; [ engineering services, biotechnology services, namely, biotechnology research in the development of therapeutic and prophylactic products and vaccines; licensing of intellectual property; ] advisory services relating to the research and development of gene therapy; consultation services in the fields of medical and scientific research in the field of professional gene therapy [; medical research and development in the field of vector production technologies ]

Chemical and biochemical products for use in gene delivery technology, namely, enzymes; chemical products for in-vitro use in laboratories and for analysis in gene delivery technology, micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, cloning vehicles and recombinant deoxyribonucleic acid variations thereof, all for in-vivo use in gene delivery technology